Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rituximab, Mabthera

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    436 result(s) found for: Rituximab, Mabthera. Displaying page 1 of 22.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-021377-36 Sponsor Protocol Number: BO22334 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: “Estudio de fase III en dos etapas, abierto, internacional, multicéntrico, aleatorizado y controlado para investigar la farmacocinética, la eficacia y la seguridad de rituximab s.c. conjuntamente c...
    Medical condition: Linfoma Folicular (LF) CD-20 psoitivo grado 1-2, 3a sin tratar previamente Previously untreated, CD20-positive follicular lymphoma (FL) grade 1-2, 3a
    Disease: Version SOC Term Classification Code Term Level
    12.1 10061170 Follicle centre lymphoma, follicular grade I, II, III LLT
    12.1 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) BE (Completed) SK (Completed) IT (Completed) DK (Completed) DE (Completed) FR (Completed) FI (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-005506-56 Sponsor Protocol Number: MabionCD20-002NHL Start Date*: 2014-11-20
    Sponsor Name:MABION S.A.
    Full Title: Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (rituximab by Hoffman-La Roche) in Patients with Diffuse Large B-cell Lymphoma
    Medical condition: CD20 positive Diffuse Large B cell Lymphoma (DLBCL) patients diagnosed according to WHO classification of lymphomas, eligible for rituximab treatment according to MabThera SmPC with life expectance...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2005-000359-13 Sponsor Protocol Number: ML18167 Start Date*: 2005-06-20
    Sponsor Name:Roche (Magyarország) Kft
    Full Title: Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients w...
    Medical condition: Patients with advanced follicular lymphoma after induction of response (CR(u) or PR) with a MabThera® (rituximab)-containing first line regimen
    Disease: Version SOC Term Classification Code Term Level
    7.1 10061170 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-004977-12 Sponsor Protocol Number: MO19872 Start Date*: 2006-06-22
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: A Phase IIIb study of MabThera® (rituximab) maintenance therapy in patients with follicular Non-Hodgkin’s Lymphoma who have responded to induction therapy.
    Medical condition: Follicular non Hodgkin's Lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) SK (Completed) IT (Completed) GR (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000721-31 Sponsor Protocol Number: RIDOSE-MS Start Date*: 2018-07-04
    Sponsor Name:Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital
    Full Title: RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS A randomized trial of long-term dosage of rituximab in multiple sclerosis The RIDOSE-MS trial is a multi-centre trial of long-term ...
    Medical condition: Patients with multiple sclerosis (MS), 20 - 52 years of age, that have completed the RIFUND-MS trial (EudraCT 2015-004116-38) will be offered to continue in this extension trial, RODOSE-MS. In addi...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-003255-39 Sponsor Protocol Number: MCL2004FI Start Date*: 2005-02-08
    Sponsor Name:The Finnish Lymphoma group
    Full Title: Treatment protocol for elderly patients with mantle cell lymphoma (MCL). A phase II study of the Finnish Lymphoma Group.
    Medical condition: Mantle cell lymphoma
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002810-37 Sponsor Protocol Number: RI-01-007 Start Date*: 2020-03-09
    Sponsor Name:Dr. Reddy’s Laboratories S.A.
    Full Title: A Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Immunogenicity and Safety of Transitioning Subjects With Rheumatoid Arthritis to Biosimilar Rituximab (DRL_RI) or Continu...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-001117-86 Sponsor Protocol Number: 16/0340 Start Date*: 2017-07-25
    Sponsor Name:University College London
    Full Title: A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP
    Medical condition: Acquired thrombotic thrombocytopenic purpura
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-005640-81 Sponsor Protocol Number: RR06/7719 Start Date*: 2007-09-04
    Sponsor Name:University of Leeds
    Full Title: A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS:
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000172-16 Sponsor Protocol Number: MO20927 Start Date*: 2007-08-24
    Sponsor Name:F. Hoffmann-La Roche Limited
    Full Title: An open-label study to characterize the safety and response rate of MabThera (Rituximab) plus chlorambucil in previously untreated patients with CD20-positive B-cell chronic lymphocytic leukemia.
    Medical condition: CD20-positive B-cell chronic lymphocytic leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002103-32 Sponsor Protocol Number: 50-03B Start Date*: 2005-03-02
    Sponsor Name:GELA-Recherche Clinique
    Full Title: Phase III multicentre open-label randomised study of ICE plus Rituximab (R-ICE) versus DHAP plus Rituximab (R-DHAP) in previously treated patients with CD 20 positive diffuse large B-cell lymphoma,...
    Medical condition: CD 20 positive diffuse large B cell lymphoma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003876-38 Sponsor Protocol Number: GP13-302 Start Date*: 2015-07-21
    Sponsor Name:Hexal AG (a Sandoz company)
    Full Title: A randomized, double- blind, controlled, parallel-group, multicenter study to assess the safety and immunogenicity of transitioning to GP2013 or re-treatment with Rituxan® or MabThera® in patients ...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005358-27 Sponsor Protocol Number: ASMAB1 Start Date*: 2006-07-12
    Sponsor Name:University Hospital of North Staffordshire
    Full Title: Efficacy of Rituximab (Mabthera) in active ankylosing spondylitis: a clinical and magnetic resonance imaging study
    Medical condition: Ankylosing spondylitis (AS) is an inflammatory condition primarily affecting the spine. The disease may remain symptomatic and progressive life-long. It is part of the family of spondyloarthropat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003213-13 Sponsor Protocol Number: PHRN07-YL MabThera Start Date*: 2007-11-07
    Sponsor Name:CHRU-Tours
    Full Title: Impact d'un traitement par le rituximab sur l'évolution des rejets aigus humoraux après transplantation rénale
    Medical condition: rejet aigu humoral (RAH) après transplantation rénale
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002274-30 Sponsor Protocol Number: BRD/05/11 Start Date*: 2005-12-14
    Sponsor Name:University College London
    Full Title: A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura.
    Medical condition: Thrombotic Thrombocytopenia Purpura
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000221-68 Sponsor Protocol Number: P100115 Start Date*: 2013-06-13
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038359 - Renal and urinary disorders 10018364 Glomerulonephritis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002378-26 Sponsor Protocol Number: STRIX-MSext001 Start Date*: 2014-11-13
    Sponsor Name:Västerbottens Läns Landsting
    Full Title: Switch To RItuXimab in MS extension An extension study of STRIX-MS - a phase 2 open label study of Rituximab in MS patients previously treated with self-injectibles using a target based therapy app...
    Medical condition: The original trial (EudraCT 2010-023021-38) recruited 74 patients with relapsing-remitting multiple sclerosis in stable condition while treated with first line injectible disease-modifying drugs (D...
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002859-13 Sponsor Protocol Number: SAKK 35/03 Start Date*: 2005-02-14
    Sponsor Name:SIAK
    Full Title: Comparing two schedules of rituximab maintenance in rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma: A randomized phase III trial
    Medical condition: rituximab-responding patients with untreated, chemotherapy resistant or relapsed follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10025634 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-002392-32 Sponsor Protocol Number: WA17045 Start Date*: 2005-11-23
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomised, placebo controlled, double-blind, parallel group, international study to evaluate the safety and efficacy of rituximab (MabThera/Rituxan) in combination with methotrexate, compared to...
    Medical condition: Active rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) GB (Completed) SE (Completed) DE (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2007-005125-30 Sponsor Protocol Number: V1.1 Start Date*: 2008-11-20
    Sponsor Name:Medizinische Universität Wien, Univ.Klinik für Dermatologie, Abteilung für Immundermatologie
    Full Title: Rituximab (Mabthera) in metastatic melanoma
    Medical condition: metastatic melanoma patients, clinical stage IIIc/IV ( AJCC2002), disease free
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 07:10:45 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA